A new generation of treatments for itch

Emilie Fowler, Gil Yosipovitch

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.

Original languageEnglish (US)
Article numberadv00027
Pages (from-to)37-45
Number of pages9
JournalActa dermato-venereologica
Issue number1
StatePublished - Jan 2020


  • Antipruritics
  • Cytokines
  • Pruritus
  • Unmyelinated nerve fibers

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'A new generation of treatments for itch'. Together they form a unique fingerprint.

Cite this